The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Investigation Into The Role Of Regulatory B Cells In Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$400,385.00
Summary
Solid organ transplantation is the most effective therapy for treating organ failure and some cancer. However, a common complication that occurs is graft rejection. The current aim is to develop procedures that reduce the risk of graft rejection without the use of immunosuppressive drugs, which can be toxic and make recipients more susceptible to infection. We are investigating the ability of a cell that is part of the immune system to down-regulate over-reactive immune responses and therefore r ....Solid organ transplantation is the most effective therapy for treating organ failure and some cancer. However, a common complication that occurs is graft rejection. The current aim is to develop procedures that reduce the risk of graft rejection without the use of immunosuppressive drugs, which can be toxic and make recipients more susceptible to infection. We are investigating the ability of a cell that is part of the immune system to down-regulate over-reactive immune responses and therefore reduce rejection.Read moreRead less
Induction Of Islet Transplant Tolerance In A Humanised Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$374,552.00
Summary
The current treatment for type 1 diabetes (T1D) is insulin therapy, but it cannot fully prevent chronic complications. Also intensive insulin use increases the risk of fatal hypoglycemia. An emerging therapy which may overcome or at least reduce these problems is the transplantation of human islet cells. But preventing the immune system from rejecting these cell transplants is still a major challenge. This study will develop new therapeutic strategies to protect these transplants from rejection.
Dendritic Cells In Graft-versus-Host Disease Following Bone Marrow Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$180,859.00
Summary
Bone marrow transplantation (BMT) is the only available curative therapy for many blood cancers such as leukaemia. Graft-versus-host disease (GVHD) occurs after BMT and is a major cause of transplant-related death. GVHD occurs when transplanted donor cells “attack” recipient tissues causing widespread damage. Gaining a more comprehensive understanding of this disease process is critically important for the design of new therapies and improvement of outcomes for transplant recipients.
The Thrombospondin-1/CD47 Axis In Kidney Transplantation.
Funder
National Health and Medical Research Council
Funding Amount
$372,528.00
Summary
Kidney transplantation is the preferred treatment for kidney failure. At transplantation when blood flow is restored to the organ, a massive burst of inflammatory and oxidative products ensues, a process known as “ischaemia-reperfusion injury” (IRI). This damages transplanted organs and activates the immune system, causing organ transplant rejection and loss. This project will investigate the TSP-1/CD47 axis and its manipulation in renal IRI as a focus for reducing organ injury, rejection and tr ....Kidney transplantation is the preferred treatment for kidney failure. At transplantation when blood flow is restored to the organ, a massive burst of inflammatory and oxidative products ensues, a process known as “ischaemia-reperfusion injury” (IRI). This damages transplanted organs and activates the immune system, causing organ transplant rejection and loss. This project will investigate the TSP-1/CD47 axis and its manipulation in renal IRI as a focus for reducing organ injury, rejection and transplant failure.Read moreRead less
Patient Tailored Anti-tumour T Cells To Prevent Relapse In Patients With Acute Myeloid Leukaemia Undergoing Allogeneic Haemopoietic Stem Cell Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$190,445.00
Summary
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.
Investigating The Potential Of Human Stem Cells To Repair The Degenerating Auditory Nerve After Deafness
Funder
National Health and Medical Research Council
Funding Amount
$310,787.00
Summary
One in four Australians is predicted to experience some form of hearing loss by 2050. Hearing loss is irreversible and the chief clinical treatment available for severe to profound hearing loss is a cochlear implant. However, cochlear implant efficacy is limited by the degeneration of the auditory nerve following hearing loss. Using stem cells, this project will develop techniques to restore function to the auditory nerve through replacement of the specialised cells that comprise it.